CVS Health (NYSE:CVS) Director Sells $187,345,164.10 in Stock

CVS Health Corporation (NYSE:CVS) Director Larry Robbins sold 1,983,538 shares of the stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the sale, the director owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. This represents a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Larry Robbins also recently made the following trade(s):

• On Thursday, May 21st, Larry Robbins sold 370,462 shares of CVS Health stock. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90.
• On Wednesday, May 20th, Larry Robbins sold 1,018,000 shares of CVS Health stock. The stock was sold at an average price of $93.82, for a total transaction of $95,508,760.00.

CVS Health Price Performance

Shares of NYSE CVS opened at $93.24 on Friday. CVS Health Corporation has a fifty-two week low of $58.50 and a fifty-two week high of $98.43. The company has a 50 day simple moving average of $80.38 and a two-hundred day simple moving average of $79.08. The company has a market capitalization of $118.97 billion, a price-to-earnings ratio of 41.08, a P/E/G ratio of 0.91 and a beta of 0.60. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter last year, the firm earned $2.25 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Analysts expect that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CVS. Morgan Stanley raised their price target on shares of CVS Health from $93.00 to $106.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Barclays raised their price target on shares of CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. JPMorgan Chase & Co. lifted their target price on shares of CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Weiss Ratings restated a “hold (c)” rating on shares of CVS Health in a research note on Friday, May 8th. Finally, DA Davidson lifted their target price on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $98.68.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Bernstein reiterated an Outperform rating and raised its price target on CVS to $106, saying the company is well positioned for a Medicare Advantage turnaround. Bernstein Sees CVS Well Positioned for Medicare Advantage Turnaround
• Positive Sentiment: Glenview Capital said CVS has delivered about an 80% total return since May 2024, reinforcing confidence in the company’s operational turnaround and long-term investment case. Glenview Capital Issues Statement on CVS Health
• Neutral Sentiment: CVS announced a collaboration with America250 to support the nation’s 250th anniversary celebration, a brand-building move that is unlikely to have a major near-term effect on earnings. CVS Health Collaborates With America250 To Support the Nation’s 250th Anniversary Celebration
• Neutral Sentiment: Recent community and philanthropic announcements, including support for military families and senior housing, add to CVS’s public-facing story but are not likely to move the shares materially on their own. CVS Health, Diocese of Camden, and The Walters Group Unite to Bring Senior Affordable Housing to Williamstown, New Jersey
• Negative Sentiment: Three major hospital systems, including affiliates tied to Mount Sinai, the University of Michigan, and the University of Kansas, sued CVS, alleging it siphoned about $250 million from the 340B drug program through reduced reimbursements. Hospitals sue CVS for allegedly siphoning $250M in 340B funds
• Negative Sentiment: Separate reports say hospital systems are expanding the 340B dispute, raising the risk of more litigation, settlement costs, and reputational pressure for CVS’s pharmacy-benefit operations. CVS Health Lawsuits Test 340B Practices And Investor Risk Assessment
• Negative Sentiment: Director Larry Robbins disclosed several large stock sales over the past few days, including a roughly $187 million sale, which can weigh on investor sentiment even though he still owns a large stake. SEC Form 4 filing

Hedge Funds Weigh In On CVS Health

A number of hedge funds have recently added to or reduced their stakes in the stock. Swiss RE Ltd. purchased a new stake in CVS Health during the fourth quarter valued at approximately $26,000. Sankala Group LLC purchased a new position in shares of CVS Health in the fourth quarter worth $28,000. Caitong International Asset Management Co. Ltd increased its stake in shares of CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 281 shares during the period. Mcguire Capital Advisors Inc. acquired a new stake in shares of CVS Health in the fourth quarter worth $28,000. Finally, Ares Financial Consulting LLC acquired a new stake in shares of CVS Health in the fourth quarter worth $29,000. 80.66% of the stock is currently owned by institutional investors.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.